ClinicalTrials.gg
CompletedNCT00482014Updated Nov 27, 2012Results posted

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

A Phase 1/2 interventional study of pemetrexed and cisplatin in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-27.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.

Enrollment
58th of 198
120 · median 58
Started
2007
with 10 others
Phase 1/2
16 of 213
2 open now
Registered
79th of 213
by date
Lead sponsor
26 of 213
Eli Lilly and Company

Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 58th largest by enrollment of the 198 interventional ones that give a count, is one of 11 that started in 2007, is one of 16 in phase 1/2, and was the 79th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inoperable non small cell lung cancer
  • No weight loss greater than 10% in 3 months prior to enrolling in trial
  • Adequate kidney function
  • Adequate liver function
  • Adequate lung function

Exclusion criteria

Exclusion Criteria:

  • Previous surgery to remove lung tumor
  • Previous chemotherapy or radiation therapy or lung cancer
  • Inability to take vitamin supplementation
  • Heart attack within past 6 months
  • Active infection
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    A: Pemetrexed + Carboplatin

    Pemetrexed + Carboplatin

    Drug: pemetrexed · Drug: carboplatin · Radiation: radiation therapy

  • Experimental
    B: Pemetrexed + Cisplatin

    Pemetrexed + Cisplatin

    Drug: pemetrexed · Drug: cisplatin · Radiation: radiation therapy

Interventions

  • Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase

    Also known as: LY231514, Alimta

  • Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43 Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles

  • Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\*minute (mg/mL\*min), administered intravenously, Days 1, 8, 22, 29 and 43 Phase 2 - dosed at AUC 5 mg/mL\*min, administered intravenously, every 21 days for 3 cycles

  • Radiationradiation therapy

    Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51 Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45

06

What researchers measure

Primary outcomes

  1. Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin

    MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).

    Time frame: Phase 1 enrollment to the end of study treatment up to Week 11

  2. Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin

    MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).

    Time frame: Phase 1 enrollment to the end of study treatment up to Week 11

  3. Phase 2 - Survival Probability at 2 Years

    Time frame: Phase 2 randomization up to 2 years

Secondary outcomes

  1. Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)

    Phase 1 pharmacology toxicity was defined as the number of participants experiencing dose limiting toxicities (DLTs). DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) \>7 days, febrile neutropenia, ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations), and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis). Grade 5 events are the events leading to the death.

    Time frame: Phase 1 enrollment up to Week 11

  2. Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)

    Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.

    Time frame: Phase 1 enrollment to the end of the study treatment up to Week 11

  3. Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events

    Phase 2 pharmacology toxicity was defined as the number of participants who experienced serious adverse events or all other nonserious adverse events during the study. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Events section.

    Time frame: Phase 2 randomization to the end of the study treatment up to 30.0 months

  4. Phase 2 - Time to Progression

    Time to disease progression was measured from randomization of Study Phase 2 to the first observation of disease progression according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Disease progression is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

    Time frame: Phase 2 randomization to measured disease progression up to 24 months

  5. Phase 2 - Median Survival

    Time frame: Phase 2 randomization to death as the result of any cause up to 30.0 month

  6. Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)

    Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.

    Time frame: Phase 2 randomization to the end of the treatment up to 30.0 months

07

Results

Posted Nov 27, 2012

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Carboplatin (Study Phase 1)Pemetrexed + Cisplatin (Study Phase 1)Pemetrexed + Carboplatin (Study Phase 2)Pemetrexed + Cisplatin (Study Phase 2)
Started9134652
Completed273529
Not completed761123
Withdrew: Withdrawal by subject1234
Withdrew: Adverse event3028
Withdrew: Death1214
Withdrew: Lack of efficacy1046
Withdrew: Sponsor decision1211

Outcome measures

PrimaryPhase 1 - Maximum Tolerated Dose (MTD) of Carboplatin

MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).

Time frame:
Phase 1 enrollment to the end of study treatment up to Week 11
Reported as:
Number · milligram/milliliter*minute (mg/mL*min)
Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin
milligram/milliliter*minute (mg/mL*min)Pemetrexed + Carboplatin Treatment Group
Phase 1 - Maximum Tolerated Dose (MTD) of CarboplatinNA
PrimaryPhase 1 - Maximum Tolerated Dose (MTD) of Cisplatin

MTD was defined as a dose at which the occurrence of at least 2 dose-limiting toxicities (DLTs) was observed. DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course, including a 2-week recovery period following completion of RT: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) lasting \>7 days, febrile neutropenia; ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations) and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis).

Time frame:
Phase 1 enrollment to the end of study treatment up to Week 11
Reported as:
Number · milligrams/meter squared (mg/m²)
Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin
milligrams/meter squared (mg/m²)Pemetrexed + Cisplatin Treatment Group
Phase 1 - Maximum Tolerated Dose (MTD) of CisplatinNA
SecondaryPhase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)

Phase 1 pharmacology toxicity was defined as the number of participants experiencing dose limiting toxicities (DLTs). DLT was defined as any of the following events occurring during the entire radiation therapy (RT) course: Grade 4 neutropenia (\<0.5 x 10\^9 cells per liter) \>7 days, febrile neutropenia, ≥Grade 3 neutropenia with fever \>38.5 degrees Celsius (°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with ≥Grade 2 bleeding, ≥Grade 3 nonhematologic toxicity (excluding nausea, vomiting, and transaminase elevations), and ≥Grade 3 pulmonary or esophageal toxicity (radiation-related pneumonitis or esophagitis). Grade 5 events are the events leading to the death.

Time frame:
Phase 1 enrollment up to Week 11
Reported as:
Number · participants
Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)
participantsPemetrexed + Carboplatin Treatment GroupPemetrexed + Cisplatin Treatment
Grade 5 Pneumocystis jiroveci pneumonia10
Grade 5 Hemoptysis (pemetrexed+Cisplatin30 mg/m² )01
SecondaryPhase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)

Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.

Time frame:
Phase 1 enrollment to the end of the study treatment up to Week 11
Reported as:
Number · percentage of participants
Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
percentage of participantsPemetrexed + Carboplatin Treatment GroupPemetrexed + Cisplatin Treatment
Complete Response (CR)0 (0.0 to 0.0)0 (0.0 to 0.0)
Partial Response (PR)11.1 (0.28 to 48.25)45.5 (16.75 to 76.62)
SecondaryPhase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events

Phase 2 pharmacology toxicity was defined as the number of participants who experienced serious adverse events or all other nonserious adverse events during the study. A summary of serious adverse events and other nonserious adverse events is located in the Reported Adverse Events section.

Time frame:
Phase 2 randomization to the end of the study treatment up to 30.0 months
Reported as:
Number · participants
Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events
participantsPemetrexed + Carboplatin Treatment GroupPemetrexed + Cisplatin Treatment Group
Serious Adverse Events21 (6.0 to 12.6)19 (8.3 to NA)
Other Nonserious Adverse Events4451
SecondaryPhase 2 - Time to Progression

Time to disease progression was measured from randomization of Study Phase 2 to the first observation of disease progression according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Disease progression is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

Time frame:
Phase 2 randomization to measured disease progression up to 24 months
Reported as:
Median · months
Phase 2 - Time to Progression
monthsPemetrexed + Carboplatin Treatment GroupPemetrexed + Cisplatin Treatment Group
Phase 2 - Time to Progression8.8 (6.0 to 12.6)13.1 (8.3 to NA)
SecondaryPhase 2 - Median Survival
Time frame:
Phase 2 randomization to death as the result of any cause up to 30.0 month
Reported as:
Median · months
Phase 2 - Median Survival
monthsPemetrexed + Carboplatin Treatment GroupPemetrexed + Cisplatin Treatment Group
Phase 2 - Median Survival18.7 (12.9 to NA)27.0 (23.2 to NA)
SecondaryPhase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)

Response rate is the percentage of participants with complete response (CR) or partial response (PR), as assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.

Time frame:
Phase 2 randomization to the end of the treatment up to 30.0 months
Reported as:
Number · percentage of participants
Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
percentage of participantsPemetrexed + Carboplatin Treatment GroupPemetrexed + Cisplatin Treatment Group
Complete Response (CR)6.5 (1.4 to 17.9)3.8 (0.5 to 13.2)
Partial Response (PR)45.7 (30.9 to 61.0)42.3 (28.7 to 56.8)
PrimaryPhase 2 - Survival Probability at 2 Years
Time frame:
Phase 2 randomization up to 2 years
Reported as:
Mean · percentage survival
Phase 2 - Survival Probability at 2 Years
percentage survivalPemetrexed + Carboplatin Treatment GroupPemetrexed + Cisplatin Treatment Group
Phase 2 - Survival Probability at 2 Years45.4 (29.5 to 60.0)58.4 (42.6 to 71.3)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Pemetrexed + Carboplatin—6/9 (66.7%)9/9 (100%)
Phase 1: Pemetrexed + Cisplatin—5/13 (38.5%)10/13 (76.9%)
Phase 2: Pemetrexed + Carboplatin—21/46 (45.7%)44/46 (95.7%)
Phase 2: Pemetrexed + Cisplatin—19/52 (36.5%)51/52 (98.1%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPhase 1: Pemetrexed + CarboplatinPhase 1: Pemetrexed + CisplatinPhase 2: Pemetrexed + CarboplatinPhase 2: Pemetrexed + Cisplatin
PyrexiaGeneral disorders0/92/132/460/52
NeutropeniaBlood and lymphatic system disorders1/91/130/460/52
Pneumocystis jiroveci pneumoniaInfections and infestations1/90/130/460/52
PneumoniaInfections and infestations1/91/132/462/52
Radiation oesophagitisInjury, poisoning and procedural complications1/90/130/462/52
Radiation pneumonitisInjury, poisoning and procedural complications1/90/131/461/52
Muscular weaknessMusculoskeletal and connective tissue disorders1/90/130/460/52
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/90/130/460/52
Cerebral infarctionNervous system disorders1/90/130/460/52
DehydrationMetabolism and nutrition disorders0/90/135/465/52
Most frequent other events
Showing 10 of 109
Most frequent other events
EventPhase 1: Pemetrexed + CarboplatinPhase 1: Pemetrexed + CisplatinPhase 2: Pemetrexed + CarboplatinPhase 2: Pemetrexed + Cisplatin
DysphagiaGastrointestinal disorders6/95/1319/4618/52
FatigueGeneral disorders6/97/1326/4627/52
NauseaGastrointestinal disorders4/95/1321/4628/52
AnaemiaBlood and lymphatic system disorders4/95/1314/4616/52
DysgeusiaNervous system disorders4/91/135/465/52
OesophagitisGastrointestinal disorders1/91/1319/4621/52
NeutropeniaBlood and lymphatic system disorders2/91/1316/4612/52
StomatitisGastrointestinal disorders3/91/132/463/52
PyrexiaGeneral disorders3/91/134/465/52
InsomniaPsychiatric disorders3/91/1311/469/52

Baseline characteristics

Age Continuous
Age Continuous(Years)Pemetrexed + Carboplatin (Study Phase 1)Pemetrexed + Cisplatin (Study Phase 1)Pemetrexed + Carboplatin (Study Phase 2)Pemetrexed + Cisplatin (Study Phase 2)Total
Mean61.9 ± 8.7061.0 ± 11.6663.6 ± 9.9264.1 ± 9.4463.4 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Carboplatin (Study Phase 1)Pemetrexed + Cisplatin (Study Phase 1)Pemetrexed + Carboplatin (Study Phase 2)Pemetrexed + Cisplatin (Study Phase 2)Total
Female24162143
Male79303177
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed + Carboplatin (Study Phase 1)Pemetrexed + Cisplatin (Study Phase 1)Pemetrexed + Carboplatin (Study Phase 2)Pemetrexed + Cisplatin (Study Phase 2)Total
Caucasian8 ± 73.37363788
African1 ± 11.735514
Hispanic0 ± 1.71102
East Asian0 ± 1.70112
West Asian (Indian sub continent0 ± 11.723914
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Carboplatin (Study Phase 1)Pemetrexed + Cisplatin (Study Phase 1)Pemetrexed + Carboplatin (Study Phase 2)Pemetrexed + Cisplatin (Study Phase 2)Total
United States9134343108
India003912
08

Study locations

11 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Angeles, California 90095, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wichita, Kansas 67214, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63110, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89135, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Burlington, North Carolina 27216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38120, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corpus Christi, Texas 78405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75390, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Temple, Texas 76508, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Delhi, 110085, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trivandrum, 695 011, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2007
First posted
Jun 4, 2007
Start
May 2007
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Nov 27, 2012
Last update
Nov 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00482014
Responsible party
Sponsor
First posted
Jun 4, 2007
Start date
May 2007
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Nov 27, 2012
Last update
Nov 27, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Carboplatin

Start the discussion